一種新型檢測(cè)方法能夠在HIV陽(yáng)性血清患者中檢測(cè)R7V抗體，從而可以幫助醫(yī)生鑒別那些非進(jìn)展性患者。

HIV患者R7V抗體陽(yáng)性能夠中和所有HIV病毒株，而無(wú)論病毒的基因型、患者的地理區(qū)域，甚至那些抗逆轉(zhuǎn)錄藥物抵抗的病毒株。當(dāng)HIV患者被檢測(cè)出血清陽(yáng)性后10年仍然無(wú)癥狀的時(shí)候，這些患者被認(rèn)為是非進(jìn)展者。這些患者CD4計(jì)數(shù)保持穩(wěn)定，病毒負(fù)荷不會(huì)升高。

這種新型檢測(cè)方法是酶聯(lián)免疫吸附法(ELISA)?？鼓孓D(zhuǎn)錄治療的療效并不會(huì)降低，但是抗病毒藥物能夠增加患者的副作用以及不方便。這項(xiàng)檢測(cè)能夠幫助醫(yī)生作出治療決定，能夠用于在開始的時(shí)候血清陽(yáng)性的非進(jìn)展者。與CD4計(jì)數(shù)和病毒負(fù)荷聯(lián)合應(yīng)用，有助于醫(yī)生決定開始或者不開始治療。

對(duì)989例HIV陽(yáng)性患者收集的血清進(jìn)行回顧性檢測(cè)分析，證實(shí)在HIV陽(yáng)性患者中出現(xiàn)R7V抗體與非進(jìn)展性之間的相關(guān)性為85.7%。該檢測(cè)已經(jīng)由Ivagen(Nimes, France)從芝加哥大學(xué)Jean Claude Chermann教授獲得了許可證。

ELISA for AIDS-Protective Antibodies
 
A new test detects the presence of anti-R7V antibodies in HIV-seropositive patients, which helps doctors to identify patients who may be nonprogressors.

Anti-R7V antibodies from HIV-positive patients have the property of neutralizing all strains of HIV, no matter the genotype, phenotype, or geographical area of the patient, even if the strain is resistant to anti-retroviral drugs. When HIV patients remain asymptomatic for more than 10 years after being detected as seropositive, they are considered as being nonprogressors. They have stable CD4 counts and viral load that does not evolve.

The new test is an enzyme-linked immunosorbent assay (ELISA). It does not discount the efficacy of anti-retroviral therapy, but the use of anti-viral agents can cause side effects and inconveniences for patients. The test helps doctors make therapeutic decisions and is used at the initiation of seropositivity to detect nonprogressors. In conjunction with CD4 counts and viral load, it helps doctors decide whether or not to apply therapy.

A retrospective study of 989 samples collected from HIV-positive patients demonstrated a correlation of 85.7% between nonprogression and the presence of anti-R7V antibodies in HIV-positive patients. The test has been licensed from Professor Jean Claude Chermann of the University of Chicago (IL, USA) by Ivagen (Nimes, France).